CD160 serves as a negative regulator of NKT cells in acute hepatic injury.

Kim, Tae-Jin; Park, Gayoung; Kim, Jeongmin; Lim, Seon Ah; Kim, Jiyoung; Im, Kyungtaek; Shin, Min Hwa; Fu, Yang-Xin et al. · Nat Commun · 2019

basic_science · Level V

Where this comes from

Abstract

CD160 and BTLA both bind to herpes virus entry mediator. Although a negative regulatory function of BTLA in natural killer T (NKT) cell activation has been reported, whether CD160 is also involved is unclear. By analyzing CD160<sup>-/-</sup> mice and mixed bone marrow chimeras, we show that CD160 is not essential for NKT cell development. However, CD160<sup>-/-</sup> mice exhibit severe liver injury after in vivo challenge with α-galactosylceramide (α-GalCer). Moreover, CD160<sup>-/-</sup> mice are more susceptible to Concanavalin A challenge, and display elevated serum AST and ALT levels, hyperactivation of NKT cells, and enhanced IFN-γ, TNF, and IL-4 production. Lastly, inhibition of BTLA by anti-BTLA mAb aggravates α-GalCer-induced hepatic injury in CD160<sup>-/-</sup> mice, suggesting that both CD160 and BTLA serve as non-overlapping negative regulators of NKT cells. Our data thus implicate CD160 as a co-inhibitory receptor that delivers antigen-dependent signals in NKT cells to dampen cytokine production during early innate immune activation.

Medical subject headings